David Natan - Jul 26, 2023 Form 4/A - Amendment Insider Report for TITAN PHARMACEUTICALS INC (TTNP)

Role
Director
Signature
/s/ David Natan
Stock symbol
TTNP
Transactions as of
Jul 26, 2023
Transactions value $
$0
Form type
4/A - Amendment
Date filed
7/31/2023, 07:45 PM
Date Of Original Report
Jul 28, 2023
Previous filing
Dec 19, 2022
Next filing
Oct 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TTNP Common Stock Award $0 +50K $0.00 50K Jul 26, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TTNP Option to Purchase Common Stock Award $0 +25K $0.00 25K Jun 29, 2023 Common Stock 25K $1.52 Direct F2, F3
transaction TTNP Option to Purchase Common Stock Award $0 +100K $0.00 100K Jun 29, 2023 Common Stock 100K $1.31 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
F2 The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.
F3 This Form 4 is being amended to correct the expiration date of the options, which were incorrectly reported in the original report due to an inadvertent clerical error.
F4 The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.